Editas Medicine Inc

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -179.84 M-163.8 M-177.35 M-132.18 M-210.28 M-165.24 M -165.24 M Mittelzufluss aus Investitionstätigkeit -140.52 M-54.47 M114.07 M-3.73 M162.15 M138.67 M 138.67 M Zahlungsströme aus der Finanzierungstätigkeit 224.12 M282.11 M1.28 M118.04 M56.03 M40.47 M 40.47 M Freier Cashflow -187 M-171.78 M-181.47 M-136.9 M-219.11 M-165.85 M -165.85 M

Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

EDIT

Financials

Editas Medicine Inc

Nachrichten

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

US-Patentamt bestätigt erneut CRISPR-Rechte des Broad Institute

EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y

Jones Trading stuft Editas Medicine hoch: Fortschritte bei Gentherapie überzeugen

Jones Trading upgrades Editas Medicine stock rating on gene therapy progress

Baird bestätigt Rating für Editas Medicine nach Fortschritten in der Pipeline/n

Baird reiterates Editas Medicine stock rating on pipeline progress

TD Cowen bestätigt Kaufempfehlung für Editas Medicine nach Pipeline-Fortschritten

TD Cowen reiterates Editas Medicine stock Buy rating on pipeline progress

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

Editas Medicine übertrifft Erwartungen – Aktie legt um 2 % zu